Genmab and Pfizer have announced that the FDA has approved the supplemental Biologics License Application for TIVDAK for the treatment of patients with recurrent or metastatic cervical cancer with disease
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
Advertisement
NLS News
Medivir’s selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease Designation (RPDD) as well as Orphan Drug Designation (ODD) for the treatment of Legg-Calvé-Perthes Disease (LCPD). The FDA
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of
Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs. The move to Research Triangle Park
About half of the 26 employees were made redundant prior to the bankruptcy and the other half have had their employment agreements terminated following the bankruptcy. As things stand, most
The company has announced the successful closure of an oversubscribed bridge financing round. Funding was provided by existing investors, such as Northern Venture CapSek, and new shareholders. The money will
Recently, the annual Entrepreneur’s Gala took place at Uppsala Castle to honor companies that showed exceptional performance during the past year and the Entrepreneur of the Year award was awarded
Researchers at Chalmers University of Technology in Sweden have carried out one of the largest studies to date using AI (artificial intelligence)-assisted image analysis of lymphoma. “An AI-based computer system
Voydeya has been approved as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. Voydeya is a
In the beginning of March, Sahlgrenska Science Park, GoCo Health Innovation City, AstraZeneca, and other members of Health Innovation West invited participants, students, researchers, tech enthusiasts, life science experts, entrepreneurs,
Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur. “Most of all,
Drug and Device Development
Sobi has announced results from the AVA-PED-301 study, evaluating the efficacy and safety of avatrombopag (Doptelet) for the treatment of paediatric patients with immune thrombocytopenia (ITP) of at least 6
The company has announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer. In the model, 177Lu-SN201 demonstrates superior anti-tumor effect compared to standard cancer
The company has announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in
Predicting 2024
Nordic Life Science asked Lene Gerlach, Partner, Eir Ventures, about her predictions for 2024, including market trends, financing opportunities for SMEs and business strategy advice. What do you predict will
Nordic Life Science asked Casper Breum, Managing Partner, Sound Bioventures, about his predictions for 2024, including market trends, financing opportunities for SMEs and business strategy advice. What do you predict
Nordic Life Science asked Ingrid Teigland Akay, Managing Partner, Hadean Ventures, about her predictions for 2024, including market trends, financing opportunities for SMEs and business strategy advice. What do you
Nordic Life Science asked Dan Akschuti, Equity Partner/Biotech Analyst, Pareto Securities, about his predictions for 2024, including market trends, financing opportunities for SMEs and business strategy advice. What do you
Nordic Life Science asked Pekka Simula, Partner, Innovestor Life Science, about his predictions for 2024, including market trends, financing opportunities for SMEs and business strategy advice. What do you predict
Upcoming events
The investor day will again bring an international flavor. Nordic and Norwegian life science investors focusing on health, bioindustrials, sustainability and life science based solutions, will meet and partner 1:1
The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and
For the past decade, Nordic Life Science Days (NLSDays) has been building business partnerships, highlighting innovations and showcasing all that the Nordic countries have to offer in the life science
Medical Devices Regulation Update: Exploring the Thriving Regulatory Landscape This year’s MedDev Day will focus on the attractiveness of the European regulatory landscape for medical devices, improvements made and future
Experience BIO-Europe and connect with delegates spanning the global life science ecosystem to propel dealmaking and innovation. Join over 5,500 attendees, representing more than 2,800 companies and over 60 countries.
Harmonizing Perspectives to Support Implementation of Common Objectives in Pharmacovigilance: Insights from the Nordic Region It is our pleasure to announce that the well-known Nordic Pharmacovigilance Day conference is taking
Careers
Promotions and hefty raises do not create leaders. While some people always want to sit in the driver’s seat, leadership – effective leadership – is a learned skill. Too often
Jeanette Edblad is the new Director of the Office for Life Sciences at the Government Offices in Sweden. NLS asked her about her new role and about Swedish life sciences.
The board of WntResearch has appointed Per Norlén as the company’s new CEO. Per Norlén has solid experience from the life science industry in general and the development of cancer
Careers
How do you take an invention further and make the right decisions to protect your innovation? Patent engineer Maria Lundström provides a helping hand in the delicate processes of patents,
JOB ALERTS
Read the latest issue of our magazine!
No 02 2024 // This issue includes a special report on obesity, including an exclusive interview with professor Jens Juul Holst, discoverer of the now world-famous GLP-1, other Nordic obesity solutions beyond GLP-1, patient perspectives, investor perspectives, a market overview, and in-depth science articles about the field. Another theme in this issue is rare diseases, an area that has undergone a minor revolution in recent decades, and where Nordic collaboration, as well as patient perspectives and involvement, are crucial. In addition, it includes an exclusive interview with Anna Falk, Head of Lund University’s Center for Advanced Therapies, and you may learn more about the importance of embracing legalese as a drug developer. This, and much more!
Profile
When considering the significant industries in Norway, several obvious ones spring to mind: oil and gas, hydropower, property, and fishing. Life sciences would feature on very few lists, but that
In the heart of Iceland’s life sciences industry, Jonina Gudmundsdottir, the CEO of Coripharma, is making her mark. With a deep understanding of the industry’s challenges and a relentless drive
The CEO of Lundbeck, who announced that she will retire last week, did not initially intend to join the life science industry, but it captivated her more than 30 years
The latest research news from the Nordic region
Science articles
An international team of scientists led by the University of Helsinki performed comprehensive mapping of structural alterations in cellular proteins during the aging process. In the study published in Molecular
The 2023 Ig Nobel Prizes celebrates for example backward reading and counting nostril hairs. The 2023 Ig Nobel Prizes were awarded at the 33rd First Annual Ig Nobel Prize ceremony,
Researchers at Karolinska Institutet have developed a molecular method able to detect whether or not bacteria respond to antibiotics within minutes. The findings are presented in the journal Nature Microbiology
Professor Jens Juul Holst has made discoveries that have strongly influenced how people with obesity or type 2 diabetes are treated today. Throughout a long career, this internationally recognized researcher
Professor Åslaug Helland is the recipient of the King Olav Vs Cancer Research Award 2023. “This is a great honor, and I am very happy about this recognition of the
In January 2023, the European Association for the Study of Obesity (EASO) and the Novo Nordisk Foundation (NNF) announced that they were establishing a new prize for an agenda-setting researcher
Nordic Life Science
The latest clinical trials
The company has announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer. In the model, 177Lu-SN201 demonstrates superior anti-tumor effect compared to standard cancer
The company has announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in
TILT Biotherapeutics has presented preliminary safety and efficacy data from their ongoing Phase I clinical trial in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer
Elypta has announced that the interim results from the LEVANTIS-0087A study will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego during the
Affibody has announced that the first patients have been dosed in a clinical basket study of the PET imaging agent 68Ga-ABY-025 for non-invasive quantification of HER2-status in solid tumors. ABY-025
Sobi has announced results from the AVA-PED-301 study, evaluating the efficacy and safety of avatrombopag (Doptelet) for the treatment of paediatric patients with immune thrombocytopenia (ITP) of at least 6
Nykode Therapeutics has announced key conclusions from the updated analysis from the Phase 2 VB-C-02 trial. The trial investigates the use of Nykode’s wholly-owned off-the-shelf therapeutic cancer vaccine candidate VB10.16
Cantargia has reported new data highlighting the potential of the CAN10 antibody, currently in phase I clinical development, as therapy in systemic sclerosis. All signaling systems targeted by CAN10 (IL-1,
Atrogi has announced the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). “This full phase 1a/b data readout
Sign up to our newsletter
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
Advertisement
